Stéphane Bancel, Moderna CEO (Endpoints JPM20/Jeff Rumans)
December 10, 2021 04:33 PM ESTUpdated 05:50 PM
R&D

Mod­er­na's flu da­ta of­fer a clear les­son: mR­NA is­n't mag­ic

Jason Mast

Editor

Last fall, as their Covid-19 vac­cine crossed the fin­ish line, Mod­er­na un­veiled plans to take its new­ly proven mR­NA plat­form and use it to ef­fec­tive­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times